12. Congenital myasthenic syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 5 / Drugs : 7 - (DrugBank : 3) / Drug target genes : 5 - Drug target pathways : 13
Drugs and their primary sponsors and trial info
3,4-DIAMINOPYRIDINE
Lahey Clinic
2001 - NCT00872950 United States;
3,4-Diaminopyridine
Ricardo Maselli
2018 - NCT03062631 United States;
3,4-diaminopyridine
Vern C. Juel, M.D.
2013 - NCT01765140 United States;
Albuterol
Mayo Clinic
2010 Phase 1 NCT01203592 United States;
Amifampridine Phosphate
Catalyst Pharmaceuticals, Inc.
2014 - NCT02189720 United States;
Lahey Clinic
2001 - NCT00872950 United States;
3,4-Diaminopyridine
Ricardo Maselli
2018 - NCT03062631 United States;
3,4-diaminopyridine
Vern C. Juel, M.D.
2013 - NCT01765140 United States;
Albuterol
Mayo Clinic
2010 Phase 1 NCT01203592 United States;
Amifampridine Phosphate
Catalyst Pharmaceuticals, Inc.
2014 - NCT02189720 United States;